A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

121

Participants

Timeline

Start Date

August 12, 2023

Primary Completion Date

April 18, 2024

Study Completion Date

April 18, 2024

Conditions

Healthy Participants

Interventions

DRUG

Semaglutide

Participants will receive Dose 1 oral semaglutide D for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days.

Trial Locations (1)

Profil Institut für Stoffwechselforschung GmbH, Neuss